Form 4: Kiniksa Pharmaceuticals International Director Receives Stoc
Insider Transaction (Form 4)
Richard S Levy, a Director of Kiniksa Pharmaceuticals International, plc, reported multiple transactions in common stock on August 1, 2026.
Summary
- Option exercise/conversion: acquired 403 Class A Ordinary Share on August 1, 2026; holds 22,359 after (Direct).
- Grant/award: acquired 403 Restricted Share Units on August 1, 2026; holds 403 after (Direct).
- Option exercise/conversion: disposed of 403 Restricted Share Units on August 1, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Richard S Levy — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-01 | Option exercise/conversion | Class A Ordinary Share | 403 | — | — | 22,359 |
| 2026-08-01 | Grant/award | Restricted Share Units | 403 | — | — | 403 |
| 2026-08-01 | Option exercise/conversion | Restricted Share Units | 403 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-01 | Option exercise/conversion (403 shares) |
| 2026-08-01 | Grant/award (403 shares) |
| 2026-08-01 | Option exercise/conversion (403 shares) |
Keywords
insider transaction, Form 4, KNSA, Kiniksa Pharmaceuticals International, plc, neutral, Richard S Levy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.